New Issue: Goldman Sachs prices $14.3 million 0.75% notes mandatorily exchangeable for Amgen

By Angela McDaniels

Seattle, Feb. 21 - The Goldman Sachs Group Inc. priced $14,300,007.49 of 0.75% buffered notes due Feb. 22, 2007, mandatorily exchangeable for common stock of Amgen Inc., according to a 424B3 filing with the Securities and Exchange Commission.

If Amgen stock finishes above the initial value of $71.063, the payout is 1 Amgen share per $71.063 principal amount, capped at $85.276, 120% of the initial stock price.

If Amgen stock finishes below the initial value but above the threshold price of $63.957 then the payout is $71.063 of Amgen stock per $71.063 note.

If Amgen stock finishes below the threshold price then investors receive 1.1111 shares.

Issuer:	Goldman Sachs Group Inc.
Issue:	Buffered mandatory exchangeable medium-term notes, series B
Underlying stock:	Amgen Inc.
Amount:	$14,300,007.49
Maturity:	Feb. 22, 2007, unless extended up to six days
Coupon:	0.75%, payable quarterly
Price:	Par of $71.063 (initial stock price of Amgen)
Payout at maturity:	If Amgen stock finishes above initial value of $71.063, 1 Amgen share per $71.063 principal amount, capped at $85.276, 120% of initial stock price; if Amgen stock finishes below initial value but above threshold price of $63.957 then $71.063 of Amgen stock per $71.063 note; if Amgen stock finishes below threshold price then 1.1111 shares
Threshold price:	$63.957, 90% of initial stock price
Pricing date:	Feb. 13
Settlement date:	Feb. 21
Agent:	Goldman, Sachs & Co.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.